Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the makers of Wegovy and Mounjaro are seeking FDA approval for tablets.
Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, becoming the first publicly ...
Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...
In summary, under the Trump plan, the U.S. health system continues to fail Americans — by not viewing obesity as a disease, ...
Unlike many pharmacies charging more than $1,000 per month for GLP-1 therapies, STL Med Weight Loss offers its program at a ...
Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month ...
Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare ...
The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling ...
Novo Nordisk (NVO stock is in focus as the company cuts prices for Wegovy in India by up to 37% to rival Eli Lilly’s (LLY) Mounjaro. Read more here.
Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what I see in store for PFE and MTSR stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback